The most notable recent finding is BWIN's three‑month outperformance (+9.5% relative to the S&P), which signals that its underwriting mix or expense management may be buffering it against the severe declines seen in peers, offering a tactical entry point for value‑seeking investors.
Investors should be cautious of the sustained negative equity growth; a cumulative -18.2% return implies that capital appreciation has been eroded, and any further deterioration in combined ratio could accelerate loss of investor capital, especially if regulatory rate hikes are limited.
Smart money concentration is fragile: if insiders cease buying and the stock fails to breach the $13.7 upper range, a reversal could trigger rapid sell‑offs, potentially adding another 10-15% decline on top of the historical -63% drawdown risk.
The most compelling growth signal is the 15.8% three‑year CAGR, which shows that BWIN can sustain double‑digit premium expansion over multiple cycles—a key driver for long‑term market share gains and future earnings upside if underwriting discipline improves.
The negative net margin of -2.2% translates to a loss of $33 M on a $1.5 B revenue base, indicating that current underwriting losses are sizable enough to offset all other income streams; if loss ratios rise even modestly (e.g., 0.5% higher), the company could swing deeper into loss and face capital adequacy concerns.
The equity multiplier's jump to 6.43 is the most striking driver of the ROE swing, signaling that Baldwin has leveraged its balance sheet heavily; this leverage magnifies losses and makes the negative ROE unsustainable without a turnaround in underwriting profitability.
| Year | ROE% | Margin% | Turnover | Leverage | ROIC% | ROCE% | ROA% |
|---|---|---|---|---|---|---|---|
| 2025 | -5.6 | -2.2 | 0.39 | 6.43 | 4.0 | 3.9 | -0.9 |
| 2024 | -4.2 | -1.8 | 0.39 | 6.06 | 2.5 | 2.4 | -0.7 |
| 2023 | -16.1 | -7.5 | 0.34 | 6.25 | -1.8 | -1.7 | -2.6 |
| 2022 | -6.9 | -4.3 | 0.28 | 5.69 | -1.1 | -1.1 | -1.2 |
| 2021 | -5.0 | -5.5 | 0.19 | 4.73 | -1.4 | -1.4 | -1.1 |
| 2020 | -4.3 | -6.8 | 0.15 | 4.16 | -1.7 | -1.7 | -1.0 |
| 2019 | -11.8 | -6.4 | 0.34 | 5.44 | -1.6 | -1.6 | -2.2 |
| 2018 | -0.4 | -0.8 | 149.61 | 0.00 | -5.0 | -118.4 | |
| 2017 | 3.8 | 3.6 | 90.17 | 0.01 | -9.3 | 324.4 |
The 0.39x asset turnover represents a >95% decline from prior periods; if revenue cannot be scaled to the enlarged asset base, ROIC will slip below cost of capital, eroding shareholder value and potentially triggering rating downgrades.
| Year | Total Asset Days | Inventory Days | Receivables Days | Fixed Asset Days | Payables Days | Cash Conversion Cycle |
|---|---|---|---|---|---|---|
| 2025 | 937 | 0 | 204 | 20 | 214 | -11 |
| 2024 | 937 | 0 | 186 | 25 | 253 | -66 |
| 2023 | 1058 | 0 | 190 | 33 | 248 | -59 |
| 2022 | 1303 | 0 | 200 | 46 | 266 | -66 |
| 2021 | 1875 | 0 | 223 | 65 | 321 | -98 |
| 2020 | 2410 | 0 | 245 | 17 | 335 | -90 |
| 2019 | 1079 | 0 | 159 | 9 | 218 | -59 |
| 2018 | 2 | 0 | 137 | 10 | 192 | -55 |
| 2017 | 4 | 0 | 37 | 8 | 45 | -9 |
| Year | Total Assets | Total Liabilities | Total Equity | Total Debt | Net Debt | Cash | Current Assets | Current Liabilities |
|---|---|---|---|---|---|---|---|---|
| 2025 | $3862M | $2778M | $600M | $1770M | $1647M | $124M | $1200M | $1033M |
| 2024 | $3535M | $2526M | $583M | $1641M | $1493M | $148M | $1026M | $1056M |
| 2023 | $3502M | $2483M | $560M | $1632M | $1516M | $116M | $926M | $1033M |
| 2022 | $3462M | $2322M | $608M | $1473M | $1355M | $118M | $772M | $699M |
| 2021 | $2876M | $1689M | $608M | $1039M | $900M | $138M | $578M | $541M |
| 2020 | $1530M | $760M | $368M | $391M | $283M | $108M | $302M | $217M |
| 2019 | $399M | $161M | $73M | $43M | $-25M | $68M | $133M | $73M |
| 2018 | $1M | $270M | $140M | $1M | $-7M | $8M | $178M | $189M |
| 2017 | $1M | $97M | $45M | $1M | $-2M | $3M | $53M | $63M |
| Year | Operating CF | Investing CF | Financing CF | CapEx | Free Cash Flow | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| 2025 | $-29M | $-140M | $204M | $-40M | $-69M | ||
| 2024 | $102M | $13M | $-30M | $-41M | $61M | $-0M | |
| 2023 | $45M | $-22M | $-26M | $-21M | $23M | $-0M | |
| 2022 | $-2M | $-414M | $420M | $-22M | $-24M | ||
| 2021 | $40M | $-678M | $724M | $-5M | $35M | ||
| 2020 | $37M | $-678M | $712M | $-5M | $31M | $-78M | |
| 2019 | $12M | $-101M | $152M | $-2M | $10M | $-44M | $-11M |
| 2018 | $12M | $-42M | $35M | $-1M | $11M | $-10M | |
| 2017 | $8M | $-14M | $4M | $-0M | $8M | $-7M |
This report is generated by Finexus and is provided for informational purposes only. It does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security.
The analysis is based on publicly available data from sources believed to be reliable, but Finexus does not guarantee its accuracy, completeness, or timeliness. Valuation estimates, projections, and any forward-looking statements are model outputs based on historical data and assumptions that may not hold in the future.
Past performance is not indicative of future results. Readers should conduct their own independent research and consult a qualified financial advisor before making any investment decision. Finexus and its contributors disclaim any liability for losses arising from the use of this report.
Created 2026-06-07 · finexus.net